Lindus Health, an anti-CRO focused on accelerating and enhancing the reliability of clinical trials, has announced it has raised $40,000,000 in new investment capital. This funding round marks a significant milestone for the company as it continues to grow its innovative approach within the life sciences sector. The capital infusion will enable Lindus Health to further develop its capabilities and expand its operational footprint.
The company distinguishes itself by running radically faster and more reliable clinical trials for life science pioneers. Its model aligns incentives through fixed-price quotes per study and milestone-based payments. Lindus Health combines a world-class clinical operations team with its proprietary AI-software platform and access to 40 million Electronic Health Records to handle the end-to-end execution of clinical studies, including design, patient recruitment, clinical data capture, monitoring, and project management. This methodology has already helped over 40 sponsors run entire clinical studies across the US, UK, and Europe up to 72.9% faster than traditional Contract Research Organizations (CROs).
The $40,000,000 in new funding is earmarked for strategic growth initiatives. These plans include scaling its operations to support an increasing number of clinical trials, further enhancing its AI-software platform, and expanding its team of clinical operations specialists. This investment underscores investor confidence in Lindus Health's disruptive model and its potential to transform clinical research. The capital will also support the company’s efforts to broaden its geographic reach and capacity, enabling it to assist more life science companies in bringing new treatments to patients more efficiently.
Looking ahead, Lindus Health aims to solidify its position as a leader in modern clinical trial execution. The company plans to leverage this new capital to continue its mission of delivering faster, more reliable trials, ultimately accelerating the development of new therapies and improving patient outcomes globally.
